联环药业：产品“苯磺酸氨氯地平片”取得注册证

Group 1 - The core point of the article is that Lianhuan Pharmaceutical has received approval from the National Medical Products Administration for its product "Amlodipine Besylate Tablets" through its subsidiary [1] - Lianhuan Pharmaceutical's revenue composition for the year 2024 is as follows: 59.36% from pharmaceutical distribution, 40.38% from pharmaceutical manufacturing, and 0.26% from other businesses [1] - As of the report date, Lianhuan Pharmaceutical has a market capitalization of 6 billion yuan [1]